4-[2-[2-[2-[2-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]butan-2-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-[2-[2-[2-[2-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]butan-2-one
• 英文别名: 4-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]butan-2-one
• 化学式: C₁₉H₃₈O₉
• 分子量: 410.5
• InChiKey: YWIROXBLHXXRKA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  28
• 可旋转键数：
  24
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  90.9
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• Insulin receptor partial agonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10689430B2

  公开（公告）日：2020-06-23

  Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.

  本研究公开了可作为胰岛素受体部分激动剂的胰岛素二聚体和胰岛素类似物二聚体。
• PYRAZINE DERIVATIVES AND USES THEREOF IN RENAL MONITORING
  申请人：MediBeacon, LLC

  公开号：EP2029554B1

  公开（公告）日：2014-03-19
• PEGYLATED DRUG-LINKERS FOR IMPROVED LIGAND-DRUG CONJUGATE PHARMACOKINETICS
  申请人：SEATTLE GENETICS, INC.

  公开号：US20160310612A1

  公开（公告）日：2016-10-27

  The present invention provides Ligand-Drug Conjugates comprising a PEG Unit in a parallel orientation to the Drug Unit. The invention provides inter alia, Ligand-Drug Conjugates (LDCs), methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates are stable in circulation, yet capable of inflicting cell death on targeted cells or inhibiting proliferation of targeted cells once its drug cargo is released in the vicinity or within targeted cells. In principle embodiments, an LDC of the present invention is represented by the structure of Formula I.
• INSULIN RECEPTOR PARTIAL AGONISTS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20190177393A1

  公开（公告）日：2019-06-13

  Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.